Gain Therapeutics Net Debt Growth & History (GANX)

Gain Therapeutics's net debt was −$20.1M for fiscal 2025.

View full Gain Therapeutics company overview

Gain Therapeutics annual net debt history

Gain Therapeutics annual net debt

Fiscal yearPeriod endedNet debtChangeGrowth
20252025-12-31−$20.1M−$10.4M
20242024-12-31−$9.7M$1.0M
20232023-12-31−$10.8M−$4.7M
20222022-12-31−$6.0M$29.2M
20212021-12-31−$35.3M−$29.0M
20202020-12-31−$6.2M

Gain Therapeutics net debt trends

Over the last five fiscal years, Gain Therapeutics's net debt decreased from −$6.2M to −$20.1M, a change of −$13.9M. The latest reported quarter, Q2 2026, shows −$12.5M.

About the metric

What net debt means

Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.

Calculation and source

How net debt is calculated

TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Gain Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about GANX yet. Start the conversation.

Write the first post